Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What would so so results look like?
What does a P failure look like, in terms of specific P data?
Or...they do not know the results yet...or, they have a hint somehow of good news and want the full data to strengthen company position.
I expect a comprehensive PR next Monday or Tuesday covering some type of update on oral K, latest on topical B, further info on mfg agreement of B OM, and possibly a first look at P results.
Maybe even a B OM contract?
My gut feel only based on qtr end upcoming and last PRs.
My guess is complete buy out and waiting for P results to determine final price. Also guess there are more than 1 suitors.
Doesn't make sense. 3 viable drug platforms with potential of market approval due to efficacy, safety, and delivery method leading to low cost, but high profit.
No, not consistent or logical
I've thought about that. Could mean nothing further to publish until results. Could mean he's feeling really confident about B, so not attempting to draw on P interim results.
Correct, how? Increasing the dose should improve efficacy or not have a significant impact for the better. How could it reduce efficacy?
Higher dose, easier trial.
Regarding P, does anyone think doubling the mg will reduce efficacy? Guess it could have some small adverse safety impact, but don't expect the doubling to reduce efficacy.
Not sure I understand some of the negativity or doubts, especially after making the trial easier than PH2a.
IMO, the company has sufficient data to suggest 300mg will perform better. The 400mg is more to see if there continues to be a dose response...further strenghtening negotiations potentially.
There was a reason why the company doubled the mg, and it wasn't because of ignorance or desparation. So, you're optimism is warranted.
January 16, 2018 PR
At recent San Francisco show:
Brilacidin-OM received an exceptional degree of attention.
A robust partnering matrix.
Brilacidin has earned a leadership position as an easily-delivered oral rinse drug candidate in OM
A $1 billion market opportunity within the next few years.
“What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential.
A newfound flurry of inbound partnership discussions at the San Francisco conferences
If P2b is successful, then wondering which direction the company should take with the drug. Sell?
To me, there is no reason to think it will not achieve at least minimal success, based on Ph2 results. 200mg did show differentiation to placebo, improving response over time, and faster response time.
P P2a results....
As previously released, the trial achieved its primary endpoint in patients treated with 200mg of oral Prurisol. Among patients participating in the study with the severest form of psoriasis, those having a baseline IGA score of 3 (“moderate”), the primary endpoint was met in 46.2% of patients who received Prurisol 200mg. This data was derived from analyses of all patients randomized across all 9 participating study sites.
Additional preliminary data analyses of secondary endpoints show patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm. This is another clear indication of the drug’s efficacy. Increases in Prurisol’s therapeutic response, upon evaluating patients at Day 56 (Week 8) and Day 84 (Week 12) of treatment, also were apparent in the Prurisol 200mg arm, suggesting an improving response over time.
In light of Prurisol’s greater efficacy in treating moderate psoriasis cases, the Company expects the next clinical trial of Prurisol will target patients with moderate to severe psoriasis, with an optimal dosing regimen continuing to be assessed.
K. Having trouble reconciling the combination of stopping K trial and the staff reductions if it's stopping just for P form.
Patents expansion?
What is news to me is the timing, the confidence they have moving forward, and the relationship with the formulator.
Also, 20 CDAs is twice as many as I was thinking.
Regarding P:
Phase 2a clearly showed some efficacy when you look at the data from different angles....
Additional preliminary data analyses of secondary endpoints show patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm. This is another clear indication of the drug’s efficacy. Increases in Prurisol’s therapeutic response, upon evaluating patients at Day 56 (Week 8) and Day 84 (Week 12) of treatment, also were apparent in the Prurisol 200mg arm, suggesting an improving response over time.
In light of Prurisol’s greater efficacy in treating moderate psoriasis cases, the Company expects the next clinical trial of Prurisol will target patients with moderate to severe psoriasis, with an optimal dosing regimen continuing to be assessed.
Value inflection point. Franchise asset. You are correct Groton68.
Imo, I think the higher dosing will also coorelate with faster impact (fewer days to clear)
I think P effects are coorelated to increase in dosage, both greater % and earlier impact.
Simply put..Amazing! Kevetrin turns on the "master switch". Is there another drug that claims this?
I agree. Spring will arrive. Medical professionals should be excited about ipix 3 drugs. As a long term investor, I am. A drug that impacts p53. Another that has platform potential.
I love the share price if P comes through.
IMO, negative P results will not impact B offers from BP. However, positive P results will make a tremendous difference for IPIX options. Better to wait another month.
Petemantx, sorry for the confusion. Meant to type B instead of P.
IMO, once partner funding starts, then price climbs. Honestly, I don't see why a large Pharma would not want to buy the company out right. I hope Leo wants to build the company rather than sell. There are many opportunities here, and if executed well then IPIX has a chance to grow rapidly but controlled.
I prefer IPIX control the trials and not rely on other companies to control. To me this means partner where we control timing and scope. After K and P results are clear, then IPIX pushes the pace, larger stafff and larger mgt teams. Meanwhile I see no reason why the company shouldn't put their resources to develop pill form of K and P. Imagine all 3 drugs being in pill form with minimal side effects.
Prelim K data suggests K helps prevent cancer. Modifies P53 resulting in tumor suppression. At just 3x per week dosing. Imagine oral pill at 3x per day.
B data suggests OM is prevented in good % of patients and delays onset in others. Not to mention the good results in UC and ABSSSI.
P data so far is on par with Otezla. Soon P2b to decide future of P.
P is marketable. Key potential attributes : oral, inexpensive, early response, minimal side effects. Ph2b should answer questions on full effectiveness. So far at same stage of trials it is on par with Otezla. Question I have is if P shows dose escalating response effectiveness. Seems to be so.
Doesn't get any clearer. Thank you, Sox.
If there is a BP that wants to buy out IPIX in full, then waiting for P results make sense. We know BOM has differentail results than lead market drug. Prevents and delays. IMO, IPIX has enough data now to position themselves for a better deal. If P comes through, then the potential deal(s) are substantial.
From a late May PR....Additional preliminary data analyses of secondary endpoints show patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm. This is another clear indication of the drug’s efficacy. Increases in Prurisol’s therapeutic response, upon evaluating patients at Day 56 (Week 8) and Day 84 (Week 12) of treatment, also were apparent in the Prurisol 200mg arm, suggesting an improving response over time.
Cellceutix is extremely proud of the Phase 2 Prurisol results. Simply put, the drug’s efficacy compares favorably with many current and various types of treatments for psoriasis (see the study linked to below), including apremilast or Otezla®, which is the leading oral FDA approved anti-psoriasis drug. It is interesting to do a side-by-side comparison between the two based on publicly available literature, and it could be argued that Prurisol performs on par with, if not better than, Otezla® at the identical stage of development
My opinion on favorable factors: oral and earlier impact are 2 big selling points.
Thank you, 123Tom and others, I have been buying in 60s and 70s. Still have funds to keep buying. The recent B OM results have caused me to increase my purchases. Waiting for P results.
Need help...assuming if share price decline is possibly due to Aspire selling, then if company inks deal with upfront payment and in theory company does not need to sell to Aspire doesn't it imply share price will increase? Not to mention the additional buying that will happen as a result of the potential BP deal.
September 14, 2017
Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial
Kevetrin
BEVERLY, Mass., Sep. 14, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that a new clinical site has been added in the Company’s Phase 2 clinical trial of Kevetrin for ovarian cancer. The site, a renowned academic medical center, is now actively enrolling patients.
In the interventional study, Kevetrin, Innovation Pharmaceutical’s novel p53-modulating drug candidate, is being evaluated in patients with platinum-resistant/refractory ovarian cancer. The primary outcomes for the study are incidence of treatment-emergent adverse events and evaluation of changes in cancer pathway biomarkers and molecular signatures, as measured in tissue/tumor samples pre-treatment and after three weeks of treatment.
“What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously.
I remember a day where some on this board were indicating p21 expression was not indicative of modulating p53. Seems to me the PR today dispelled that line of thinking...with direct evidence.
B OM results were not as impressive as interim results. The fact that it has an impact in reducing the incidence is unprecedented. Even better if also reduces duration.
As there are currently no approved drugs for prevention of severe OM in patients receiving chemoradiation treatment of HNC, management opinion is that Brilacidin-OM has the potential to rapidly assume a lead position after market introduction. This perspective is shared by multiple Pharma companies, potential partners the Company currently is in active discussions with, equally interested in the continued development and eventual market introduction of Brilacidin-OM worldwide.